Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data

Rahul Banerjee, Christy Khouderchah, Othman Salim Akhtar, Emily C. Liang, Jordan Gauthier, Madhav V. Dhodapkar, Andrew J. Portuguese

Blood blood.2025031426.

https://doi.org/10.1182/blood.2025031426

Published: 2025

Includes: Supplemental data

Journal Articles

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Blood (2025) 146 (Supplement 1): 928.

https://doi.org/10.1182/blood-2025-928

Published: 2025

Journal Articles

A phase 1b/2a study of CTO1681 for the prevention of cytokine release syndrome in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy

Jordan Gauthier, Matthew Frigault, Arthur Bertolino, Michael Howell, Teresa Whalen

Blood (2025) 146 (Supplement 1): 5955.

https://doi.org/10.1182/blood-2025-5955

Published: 2025

Journal Articles

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Blood (2025) 146 (Supplement 1): 667.

https://doi.org/10.1182/blood-2025-667

Published: 2025

Journal Articles

Evaluation of CAR-T access barriers in Washington and Alaska: A single-center experience prior to implementing program capacity expansion

Melinda Biernacki, Agie Cole, Kausar Abukar, Isatou Barrow, Lorenzo Iovino, Natalie Wuliji, Mohamed Sorror, Erik Kimble, Edus Warren, Ryan Cassaday, Jordan Gauthier, Meredith Durbin, Alexandre Hirayama, Brian Till, Aude Chapuis, Filippo Milano, Lawrence Fong, Mazyar Shadman, Folashade Otegbeye

Blood (2025) 146 (Supplement 1): 6202.

https://doi.org/10.1182/blood-2025-6202

Published: 2025

Journal Articles

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 798.

https://doi.org/10.1182/blood-2025-798

Published: 2025

Journal Articles

Independent assessment of ALC thresholds currently in use to predict motor/neurocognitive toxicities (MNTs) after treatment with ciltacabtagene autoleucel

Yein Jeon, Xiancheng Wu, Christy Khouderchah, Emily Liang, Andrew Portuguese, Jennifer Huang, Erik Kimble, Alexandre Hirayama, Mazyar Shadman, Andrew Cowan, Danai Dima, Rahul Banerjee, Madhav Dhodapkar, Lawrence Fong, Qian Wu, Meredith Durbin, Jordan Gauthier

Blood (2025) 146 (Supplement 1): 4147.

https://doi.org/10.1182/blood-2025-4147

Published: 2025

Journal Articles

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Blood (2025) 145 (23): 2762–2767.

https://doi.org/10.1182/blood.2024026831

Published: 2025

Includes: Supplemental data

Journal Articles

Trial in Progress: ST-067 (decoy-resistant IL-18) with Teclistamab in Multiple Myeloma

Rahul Banerjee, Jacquelin Vandermeer, Jeremy Barton, Michael Mangone, Beatrice P. McQueen, Jordan Gauthier, Aaron M Ring, Ajay K. Gopal, Geoffrey R. Hill, Andrew J. Cowan

Blood (2024) 144 (Supplement 1): 7100.

https://doi.org/10.1182/blood-2024-198751

Published: 2024

Journal Articles

TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia

Erik L Kimble, Salvatore Fiorenza, Alexandre V. Vinaud Hirayama, Austin M Gabel, Jordan Gauthier, Aiko Torkelson, Abigail Chutnik, Henna Di, Jocelyn H Wright, Barbara Pender, Stefan Radtke, Roland B. Walter, Hans-Peter Kiem, David G. Maloney, Robert K. Bradley, Cameron J. Turtle

Blood (2024) 144 (Supplement 1): 3422.

https://doi.org/10.1182/blood-2024-207966

Published: 2024

Journal Articles

A Comparison of Different Comorbidity Indices in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): Comprehensibility Vs Simplicity Vs Objectivity

Lorenzo Iovino, Ningxin Ma, Chris Davis, Linda M Glockling, Sophie L Martin, Filippo Milano, Jordan Gauthier, Naveed Ali, Ted Gooley, Qian Vicky Wu, Mohamed Sorror

Blood (2024) 144 (Supplement 1): 4919.

https://doi.org/10.1182/blood-2024-193595

Published: 2024

Journal Articles

Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center

Andrew J Portuguese, Mahnoosh Taheri, Rahul Banerjee, Kara I. Cicero, Mary Kwok, Natalie Wuliji, Lorenzo Iovino, Alexandre V. Vinaud Hirayama, Erik L Kimble, Leona Holmberg, Mazyar Shadman, Jordan Gauthier, David G. Maloney, Andrew J. Cowan

Blood (2024) 144 (Supplement 1): 3772.

https://doi.org/10.1182/blood-2024-201092

Published: 2024

Journal Articles

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

Jennifer J. Huang, Namrata Singh, Mazyar Shadman, Ryan S. Basom, Andrea Kalus, Andrew J Portuguese, Emily C Liang, Natalie Wuliji, Alexandre V. Vinaud Hirayama, Aude G Chapuis, Folashade Otegbeye, Filippo Milano, Ryan D. Cassaday, Ajay K. Gopal, Brian G. Till, Edus H. Warren, Jordan Gauthier, Lawrence Fong, David G. Maloney

Blood (2024) 144 (Supplement 1): 7132.

https://doi.org/10.1182/blood-2024-201809

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Blood (2024) 144 (Supplement 1): 4633.

https://doi.org/10.1182/blood-2024-200840

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Blood (2024) 144 (Supplement 1): 887.

https://doi.org/10.1182/blood-2024-200339

Published: 2024

Journal Articles

Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming

Salvatore Fiorenza, Yue Cao, Ye Zheng, Janaki Purushe, Tamara Bock, Erik L Kimble, Derek Janssens, Delaney Kirchmeier, Alexandre V. Vinaud Hirayama, Jordan Gauthier, David G. Maloney, Stanley R. Riddell, Akira Nguyen-Shaw, Steven Henikoff, Jean Yang, Cameron J. Turtle

Blood (2024) 144 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2024-200589

Published: 2024

Journal Articles

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

Eleftheria Kampouri, Elizabeth M. Krantz, Hu Xie, Sarah S. Ibrahimi, Erika S. Kiem, Mandeep K. Sekhon, Emily C. Liang, Andrew J. Cowan, Andrew Portuguese, Damian J. Green, Aya Albittar, Jennifer J. Huang, Jordan Gauthier, Ailyn C. Pérez-Osorio, Keith R. Jerome, Danielle M. Zerr, Michael J. Boeckh, Joshua A. Hill

Blood (2024) 144 (5): 490–495.

https://doi.org/10.1182/blood.2024024145

Published: 2024

Includes: Supplemental data

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Journal Articles

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Andrew J Portuguese, Aya Albittar, Emily C Liang, Jennifer J. Huang, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Hans-Peter Kiem, Filippo Milano, Aude G Chapuis, Folashade Otegbeye, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2023-172978

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

A phase 1b/2a study of CTO1681 for the prevention of cytokine release syndrome in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Evaluation of CAR-T access barriers in Washington and Alaska: A single-center experience prior to implementing program capacity expansion

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Independent assessment of ALC thresholds currently in use to predict motor/neurocognitive toxicities (MNTs) after treatment with ciltacabtagene autoleucel

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Trial in Progress: ST-067 (decoy-resistant IL-18) with Teclistamab in Multiple Myeloma

TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia

A Comparison of Different Comorbidity Indices in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): Comprehensibility Vs Simplicity Vs Objectivity

Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only